Screener
Ironwood Pharmaceuticals IRWD Cash & Equivalents
Cash & Equivalents at other companies
Other financials
Where this comes from
Reported directly by Ironwood Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue.
The source filing: Ironwood Pharmaceuticals’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-091987
FAQ
- What is Ironwood Pharmaceuticals's cash & equivalents?
- Ironwood Pharmaceuticals (IRWD) reported cash & equivalents of $79.13M in Q2 2026.
- How has Ironwood Pharmaceuticals's cash & equivalents changed year-over-year?
- Ironwood Pharmaceuticals's cash & equivalents decreased by 14.8% year-over-year, from $92.85M to $79.13M.
- What is the long-term trend for Ironwood Pharmaceuticals's cash & equivalents?
- Over 5 years (2020 to 2025), Ironwood Pharmaceuticals's cash & equivalents has grown at a -9.9% compound annual growth rate (CAGR), from $362.56M to $215.46M.
- What does cash & equivalents mean?
- Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.
Ask your AI about Ironwood Pharmaceuticals's cash & equivalents.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude